January 4, 2021

ImmunityBio Simulates SARS-CoV-2 Spike Protein Binding Using Molecular Dynamics

CULVER CITY, Calif.–(BUSINESS WIRE)–ImmunityBio, a privately-held immunotherapy company, today announced the results of a highly detailed computer-based molecular dynamics (MD) simulation, conducted in collaboration with Microsoft Corporation, that allowed visualization of the behavior of the SARS-CoV-2 “spike” protein. The simulation provides an explanation for the virulence of the COVID-19 virus and has the potential to give researchers a roadmap for developing tools to disable the virus an

Leave Comment

Your Name *
Your Email *
Your Website
Comment *